Exact Sciences (EXAS) Scheduled to Post Earnings on Wednesday

Exact Sciences (NASDAQ:EXAS) is set to post its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Exact Sciences to post earnings of ($0.50) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.26. The business had revenue of $646.89 million for the quarter, compared to analyst estimates of $638.83 million. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. The company’s quarterly revenue was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.72) EPS. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Exact Sciences Stock Up 2.5 %

Shares of EXAS opened at $62.07 on Monday. The company has a current ratio of 2.32, a quick ratio of 2.07 and a debt-to-equity ratio of 0.74. The firm has a market cap of $11.41 billion, a P/E ratio of -54.45 and a beta of 1.26. The company’s 50-day moving average price is $63.37 and its 200 day moving average price is $64.72. Exact Sciences has a 12-month low of $56.05 and a 12-month high of $100.77.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EXAS. TheStreet cut shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Canaccord Genuity Group decreased their price target on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, Citigroup reiterated a “buy” rating and issued a $100.00 price objective on shares of Exact Sciences in a research note on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Exact Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of Exact Sciences stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the completion of the sale, the executive vice president now directly owns 73,787 shares of the company’s stock, valued at approximately $5,165,090. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the sale, the executive vice president now directly owns 73,787 shares of the company’s stock, valued at $5,165,090. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin T. Conroy sold 1,155 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the transaction, the chief executive officer now directly owns 1,156,191 shares of the company’s stock, valued at approximately $69,544,888.65. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 70,611 shares of company stock worth $4,255,377. Corporate insiders own 1.30% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.